Link to this page
Healthcare Common Procedure Coding System
Last uploaded:
August 28, 2024
Jump to:
| Preferred Name | Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | |
| Synonyms |
|
|
| ID |
http://purl.bioontology.org/ontology/HCPCS/Q2041 |
|
| cui |
C4746476
|
|
| HAC |
N=No maintenance for this code
|
|
| HAD |
20190101
|
|
| HAQ |
0
|
|
| HBT |
O1E=Other drugs
|
|
| HCC |
C=Carrier judgment
|
|
| HCD |
20180401
|
|
| HMP |
A=Not applicable as HCPCS priced under one methodology
|
|
| HPI |
51=Drugs
|
|
| HTS |
1=Medical care
|
|
| notation |
Q2041
|
|
| prefLabel |
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
|
|
| tui |
T200
|
|
| subClassOf |
http://purl.bioontology.org/ontology/HCPCS/Level%202%3A%20Q2004-Q2056 |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |